Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Click below to view/download the video:
https://physicianresources.dana-farber.org/videos/shayna-sarosiek-md-discusses-wm-net-1-trial